Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer()()

A recent phase III trial of the MET kinase inhibitor cabozantinib in men with castration-resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most men with CRPC have intact androgen receptor (AR) signaling. As previous work supports negative regulation of MET by A...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neoplasia
Main Authors: Qiao, Yuanyuan, Feng, Felix Y., Wang, Yugang, Cao, Xuhong, Han, Sumin, Wilder-Romans, Kari, Navone, Nora M., Logothetis, Christopher, Taichman, Russell S., Keller, Evan T., Palapattu, Ganesh S., Alva, Ajjai S., Smith, David C., Tomlins, Scott A., Chinnaiyan, Arul M., Morgan, Todd M.
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4735600/
https://ncbi.nlm.nih.gov/pubmed/26806347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2015.11.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados